What is the cost of delayed diagnosis of bile acid malabsorption and bile acid diarrhoea?
| Autor: | Laura White, Darren Fernandes, H. Jervoise N. Andreyev, Dennis Poon |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pediatrics
medicine.medical_specialty medicine.drug_class Cost effectiveness Population 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine 030212 general & internal medicine Medical diagnosis education Irritable bowel syndrome education.field_of_study Hepatology Bile acid business.industry Gastroenterology Bile acid malabsorption medicine.disease Taurocholic acid Small bowel and Nutrition chemistry 030211 gastroenterology & hepatology business SeHCAT |
| Zdroj: | Frontline gastroenterology. 10(1) |
| ISSN: | 2041-4137 |
| Popis: | Introduction75Selenium taurocholic acid (SeHCAT) scanning diagnoses bile acid malabsorption/bile acid diarrhoea (BAM/BAD) and defines optimal treatment. Approximately 2% of the population have BAM/BAD.AimTo evaluate the cost of delayed diagnosis of BAM/BAD.MethodsPatients’ notes who underwent SeHCAT scanning in three hospitals over a 1-year period were reviewed retrospectively. Scan results and treatment response were recorded. Package-of-care costs were calculated using costing tools from the National Institute for Health and Care Excellence and from United Lincolnshire Hospitals Trust business unit.ResultsBetween June 2016 and May 2017, 19 men and 37 women (median age 58 (range 19–83)) of 3860 new patients seen in gastroenterology clinics were referred for SeHCAT scanning. Sixty-four per cent of scans were abnormal: 13 demonstrated severe (ConclusionsSeHCAT is underused. Late diagnosis leads to unnecessary demands for other services and treatment delay. Early diagnosis achieves health benefits while reducing costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|